Skip to content
Screener

Organogenesis Holdings Inc. ORGO Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue$43.8MMiss by $10.5M
EPS-$0.71Miss by $0.36
Revenue estimate$54.3M
EPS estimate-$0.35
“Our business is built on efficacy and outcomes, and that is driving our expanding share as the market resets and customers turn to solutions they can trust. We remain convinced that we occupy the strongest long-term position and will remain the leader with the best evidence-based regenerative medicine products, while advancing the ReNu program to unlock new markets for the company.”
Gary S. Gillheeney

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$52.1M
EPS estimate-$0.18

Financials

Q2 2026

Income statement

See full
Revenue$43.8M-56.7%
Operating income-$51.0M-305%
Net income-$96.3M-925%
EPS (diluted)-$0.77-670%

Balance sheet

See full
Cash & equivalents$46.1M-36.9%
Total debt$36.6M+19.2%
Total equity$148.3M-36.4%
Total assets$406.4M-11.9%

Cash flow

See full
Operating cash flow-$31.7M+3.7%
CapEx$1.1M-69.8%
Free cash flow-$32.8M+10.3%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$178.86M-69.5%
Enterprise value$169.33M-68.9%
P/S0.4×-1.0×

Profitability

See full
Operating margin-7.8%—
Net margin-18.4%-20.8pp

Returns & leverage

See full
Return on equity-44.1%-48.0pp
Debt / equity0.2×+0.1×
Current ratio3.5×-0.4×

Segments

By product

See full
Grant$950.0K+320%

FAQ

When did Organogenesis Holdings Inc. report Q2 2026 earnings?
Organogenesis Holdings Inc. (ORGO) reported Q2 2026 earnings on August 6, 2026 after market close.
What were Organogenesis Holdings Inc.'s Q2 2026 revenue and EPS?
Organogenesis Holdings Inc. reported revenue of $43.8M and eps of $-0.71 for Q2 2026.
Did Organogenesis Holdings Inc. beat estimates in Q2 2026?
Revenue missed the consensus estimate of $54.3M by $10.5M. EPS missed the consensus estimate of $-0.35 by $0.36.
How did Organogenesis Holdings Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 56.7% from $101.0M a year earlier and eps declined 688.9% from $-0.09.
Where can I find Organogenesis Holdings Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-338022) and the 10-Q periodic report (0001193125-26-338049) directly on SEC EDGAR. The filing index links above go to sec.gov.